- Trial Phase
- Phase 2a
- Time to Market
- Likely years away if ever; nimacimab is currently in Phase 2a (Part C expansion), with Phase 2b design under FDA review but not yet funded. The Redx reverse merger monetizes the asset via CVR — further development by Skye/Fibrx is uncertain.
- Why 5/10
- The single next hard catalyst is the Part C expansion topline data from the Phase 2a CBeyond trial, expected Q4 2026 — but nimacimab is being monetized via CVR as Skye reverse-merges with Redx Pharma (forming Fibrx Therapeutics), so the drug's impact on SKYE's share price is now indirect and secondary to the deal's closing mechanics, warranting a moderate score of 5.
Monitor the Q4 2026 Part C expansion topline data for nimacimab, which could drive value in the CVR. However, with the Redx reverse merger pending (expected Q4 2026 close), pre-merger SKYE shares now primarily represent ~5.38% of the future Fibrx Therapeutics, with nimacimab upside limited to the CVR — extreme caution is warranted for equity holders.
Price Chart
Executive Summary
nimacimab is a peripherally restricted CB1 receptor inverse agonist (a 'blocker of the munchies receptor' that avoids brain side effects) being developed by Skye Bioscience (SKYE) for obesity. Phase 2a data showed a compelling 22.3% mean weight loss at 52 weeks in combination with semaglutide, and a Part C dose-expansion study is underway with topline data expected Q4 2026. However, Skye announced a transformative reverse merger with Redx Pharma (Aug 14, 2026) that will dilute existing shareholders to ~5.38% ownership of the combined Fibrx Therapeutics entity. nimacimab is being monetized separately via Contingent Value Rights (CVRs) entitling SKYE shareholders to 90% of net proceeds within 12 months of deal close. With cash runway only through Q4 2026, heavy insider selling, and the stock down ~95% from its 52-week high of $39.92, nimacimab's value to SKYE shareholders is now tied primarily to the CVR — making the fundamental thesis highly speculative and diluted.
How It Works
nimacimab is a peripherally restricted CB1 (cannabinoid-1) receptor inverse agonist. In plain terms, it blocks the 'munchies' receptor (the same one activated by cannabis) but is designed to work only in the body's peripheral tissues — fat, liver, muscle, pancreas — and not cross into the brain. This avoids the psychiatric side effects (depression, anxiety, suicide risk) that sank the first-generation brain-penetrant CB1 blocker, rimonabant. By blocking peripheral CB1 receptors, nimacimab is thought to reduce appetite, increase energy expenditure, and improve metabolic parameters, making it a potential obesity treatment — especially as an add-on to GLP-1 drugs like semaglutide.
Trial Status
nimacimab's CBeyond Phase 2a trial is in a Part C dose-expansion phase testing higher IV doses (400 mg and 600 mg). Prior Parts A/B showed 22.3% mean weight loss at 52 weeks combined with semaglutide. The first Part C patient was dosed in April 2026. FDA has provided feedback on the proposed Phase 2b design, but progression depends on Part C data and capital availability. Topline Part C data expected Q4 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 2a Part C expansion topline data — Q4 2026
- Redx Pharma reverse merger shareholder vote and close — expected Q4 2026
- Potential nimacimab monetization/partnering within 12 months post-close (per CVR terms)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Skye Bioscience, Inc. Press Release SKYE ·Originating report